Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is drawing attention to its two key assets: Lucid-MS, a drug candidate targeting mobility loss in multiple sclerosis, and unbuzzd(TM), a commercial product for alcohol metabolism. The company was featured on the BioMedWire Podcast, where co-founder Anthony Durkacz discussed the unmet need in MS treatment and the growth opportunities for both products.
Lucid-MS is designed to address nerve damage that leads to mobility loss in multiple sclerosis patients. Durkacz emphasized that current therapies do not adequately target this underlying mechanism. The company is preparing for a Phase 2 clinical trial, the first study to evaluate Lucid-MS in MS patients after successful Phase 1 testing in healthy volunteers. This trial represents a critical milestone for the drug candidate.
In addition to its pipeline, Quantum BioPharma has a commercial product, unbuzzd(TM), which accelerates blood alcohol metabolism and is available in the U.S. market. The company retains a 19.84% stake in Unbuzzd Wellness Inc., which markets the over-the-counter version, and receives royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. This arrangement provides a recurring revenue stream that could support further research and development.
The combination of a promising drug candidate in late-stage development and a revenue-generating commercial product positions Quantum BioPharma for potential growth. The company’s focus on neurodegenerative and metabolic disorders, along with alcohol misuse, addresses significant health challenges with substantial market opportunities.
For more details, the full press release is available at https://ibn.fm/HURxt. Investors can also access the latest news and updates on QNTM at the company’s newsroom: https://ibn.fm/QNTM.
